The New York Times editorial board recently observed: “We shouldn’t be surprised by any biotech’s failure. We should expect it. Biotechs by their nature offer the promise of disruptive breakthroughs and discoveries, but they’re mostly all-in propositions, based on one molecule or one test. Fail in a Phase III clinical trial — and a majority do — […]
Smithsonian magazine publishes story about impact of MSU alum, vaccinologist Maurice Hilleman From MSU News Service FEBRUARY 23, 2018 BOZEMAN — The work and impact of a Montana State University alumnus was featured recently in a prominent national forum. “You Should Thank Maurice Hilleman for Helping You Live Past the Age of 10”was published […]
The BIO Investor Forum is the premier event for emerging private and public companies to connect with prospective investors to make the deals that drive our industry. More than 220 investors are already registeredfor this year, with one month to go. The foundation for the success of an event of such magnitude as BIO Investor Forum rests on […]
Climbing The Funding Ladder in Research and Drug Development
Now Accepting Applications for Three ITHS Career Development Programs
Stan Abel of SiteOne Therapeutics to Serve as Chairman Of the Board of Montana’s Leading Biotechnology Innovation Organization; Jay Evans of Inimmune and Tim Layton of Genentech Elected to the Board of Directors Billings, MT – Wednesday, August 16, 2017 – The Montana BioScience Alliance recently elected three new board members and appointed new […]
Article originally posted at: http://www.montana.edu/news/17049/msu-scientist-publishes-findings-that-may-explain-how-cancerous-tumors-survive-after-treatment BOZEMAN – A Montana State University scientist recently published research that may explain how some cancerous tumors persist and continue to grow even after undergoing treatments that kill the cancerous cells. The new findings were published in June in the journal Cell Reports and come from furthering research published two years […]
